Cancer Research The Future of Cancer Research: Science and Patient Impact Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dowlati, A.
Right arrow Articles by Remick, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dowlati, A.
Right arrow Articles by Remick, S. C.
[Cancer Research 62, 3408-3416, June 15, 2002]
© 2002 American Association for Cancer Research

Clinical Investigations

A Phase I Pharmacokinetic and Translational Study of the Novel Vascular Targeting Agent Combretastatin A-4 Phosphate on a Single-Dose Intravenous Schedule in Patients with Advanced Cancer1

Afshin Dowlati, Kelly Robertson, Matthew Cooney, William P. Petros, Michael Stratford, John Jesberger, Niusha Rafie, Beth Overmoyer, Vinit Makkar, Bruce Stambler, Anne Taylor, John Waas, Jonathan S. Lewin, Keith R. McCrae and Scot C. Remick2

Division of Hematology/Oncology, Department of Medicine [A. D., M. C., B. O., V. M., J. W., K. R. M., S. C. R.], and Division of Cardiology, Department of Medicine [B. S.], Case Western Reserve University (CWRU), School of Medicine, Cleveland, Ohio, 44106; Developmental Therapeutics Program, Comprehensive Cancer Center at University Hospitals of Cleveland and CWRU [A. D., K. R., B. O., V. M., K. R. M., S. C. R.], and Division of Magnetic Resonance Imaging, Department of Radiology, University Hospitals of Cleveland and CWRU, School of Medicine [J. J., N. R., J. S. L.], Cleveland, Ohio 44106; Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, West Virginia 26506 [W. P. P.]; Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, HA6 2JR, United Kingdom [M. S.]; Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455 [A. T.]

Combretastatin A-4 phosphate (CA4P) is a novel antitumor vascular targeting agent, the first agent of this class of compounds to enter the clinic. We performed a Phase I trial to determine the maximum-tolerated dose, safety, and pharmacokinetic profile of CA4P on a single-dose i.v. schedule. We also obtained preliminary data on its effect on tumor blood flow using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) techniques and cell adhesion molecules at the higher-dose levels. Twenty-five assessable patients with advanced cancer received a total of 107 cycles over the following dose escalation schema: 18, 36, 60, 90 mg/m2 as a 10-min infusion and 60 mg/m2 as a 60-min infusion at 3-week intervals. There was no significant myelotoxicity, stomatitis, or alopecia. Tumor pain was a unique side effect, which occurred in 10% of cycles, and there were four episodes of dose-limiting toxicity at dosages >=60 mg/m2, including two episodes of acute coronary syndrome. Pharmacokinetics revealed rapid dephosphorylation of the parent compound (CA4P) to combretastatin A4 (CA4), with a short plasma half-life (~30 min). A significant (P < 0.03) decline in gradient peak tumor blood flow by DCE-MRI in six of seven patients treated at 60 mg/m2 was observed. A patient with anaplastic thyroid cancer had a complete response and is alive 30 months after treatment. The toxicity profile is consistent with a drug that is "vascularly active" and devoid of traditional "cytotoxic" side effects. Dosages <=60 mg/m2 as a 10-min infusion define the upper boundary of the maximum-tolerated dose.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. Dowlati, R. Gray, A. B. Sandler, J. H. Schiller, and D. H. Johnson
Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non-Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab--an Eastern Cooperative Oncology Group Study
Clin. Cancer Res., March 1, 2008; 14(5): 1407 - 1412.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
A. Saad, R. Beto, J. Abraham, and S. C. Remick
Cardiovascular Safety and Toxicity Profile of New Molecularly Targeted Anticancer Agents
ASCO Educational Book, January 1, 2008; 2008(1): 428 - 434.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Aprile, E. Del Grosso, G. C. Tron, and G. Grosa
In Vitro Metabolism Study of Combretastatin A-4 in Rat and Human Liver Microsomes
Drug Metab. Dispos., December 1, 2007; 35(12): 2252 - 2261.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H.-L. Lin, S.-H. Chiou, C.-W. Wu, W.-B. Lin, L.-H. Chen, Y.-P. Yang, M.-L. Tsai, Y.-H. Uen, J.-P. Liou, and C.-W. Chi
Combretastatin A4-Induced Differential Cytotoxicity and Reduced Metastatic Ability by Inhibition of AKT Function in Human Gastric Cancer Cells
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 365 - 373.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Overmoyer, P. Fu, C. Hoppel, T. Radivoyevitch, R. Shenk, M. Persons, P. Silverman, K. Robertson, N. P. Ziats, J. K. Wasman, et al.
Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin
Clin. Cancer Res., October 1, 2007; 13(19): 5862 - 5868.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. L. Strevel, D. J. Ing, and L. L. Siu
Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval
J. Clin. Oncol., August 1, 2007; 25(22): 3362 - 3371.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S.-C. J. Yeung, M. She, H. Yang, J. Pan, L. Sun, and D. Chaplin
Combination Chemotherapy Including Combretastatin A4 Phosphate and Paclitaxel Is Effective against Anaplastic Thyroid Cancer in a Nude Mouse Xenograft Model
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2902 - 2909.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Jackson, J. P.B. O'Connor, G. J.M. Parker, and G. C. Jayson
Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Clin. Cancer Res., June 15, 2007; 13(12): 3449 - 3459.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Senan and E. F. Smit
Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy
Oncologist, April 1, 2007; 12(4): 465 - 477.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Rosen and M. D. Schnall
Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessing Tumor Vascularity and Vascular Effects of Targeted Therapies in Renal Cell Carcinoma
Clin. Cancer Res., January 15, 2007; 13(2): 770s - 776s.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Thomson, M. A. Naylor, S. A. Everett, M. R.L. Stratford, G. Lewis, S. Hill, K. B. Patel, P. Wardman, and P. D. Davis
Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4.
Mol. Cancer Ther., November 1, 2006; 5(11): 2886 - 2894.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Hidalgo, M. L. Amador, A. Jimeno, H. Mezzadra, P. Patel, A. Chan, M. E. Nielsen, A. Maitra, and S. Altiok
Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.
Mol. Cancer Ther., July 1, 2006; 5(7): 1895 - 1903.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. J. van Heeckeren, S. Bhakta, J. Ortiz, J. Duerk, M. M. Cooney, A. Dowlati, K. McCrae, and S. C. Remick
Promise of New Vascular-Disrupting Agents Balanced With Cardiac Toxicity: Is It Time for Oncologists to Get to Know Their Cardiologists?
J. Clin. Oncol., April 1, 2006; 24(10): 1485 - 1488.
[Full Text] [PDF]

Home page
 JCOHome page
L. V. Beerepoot, S. A. Radema, E. O. Witteveen, T. Thomas, C. Wheeler, S. Kempin, and E. E. Voest
Phase I Clinical Evaluation of Weekly Administration of the Novel Vascular-Targeting Agent, ZD6126, in Patients With Solid Tumors
J. Clin. Oncol., April 1, 2006; 24(10): 1491 - 1498.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Dowlati, K. Robertson, T. Radivoyevitch, J. Waas, N. P. Ziats, P. Hartman, F. W. Abdul-Karim, J. K. Wasman, J. Jesberger, J. Lewin, et al.
Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416
Clin. Cancer Res., November 1, 2005; 11(21): 7938 - 7944.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
H. C. Thoeny, F. De Keyzer, V. Vandecaveye, F. Chen, X. Sun, H. Bosmans, R. Hermans, E. K. Verbeken, C. Boesch, G. Marchal, et al.
Effect of Vascular Targeting Agent in Rat Tumor Model: Dynamic Contrast-enhanced versus Diffusion-weighted MR Imaging
Radiology, November 1, 2005; 237(2): 492 - 499.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
H. C. Thoeny, F. De Keyzer, F. Chen, Y. Ni, W. Landuyt, E. K. Verbeken, H. Bosmans, G. Marchal, and R. Hermans
Diffusion-weighted MR Imaging in Monitoring the Effect of a Vascular Targeting Agent on Rhabdomyosarcoma in Rats
Radiology, March 1, 2005; 234(3): 756 - 764.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. H. Bilenker, K. T. Flaherty, M. Rosen, L. Davis, M. Gallagher, J. P. Stevenson, W. Sun, D. Vaughn, B. Giantonio, R. Zimmer, et al.
Phase I Trial of Combretastatin A-4 Phosphate with Carboplatin
Clin. Cancer Res., February 15, 2005; 11(4): 1527 - 1533.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. F. Jordan, M. Runquist, N. Raghunand, R. J. Gillies, W. R. Tate, G. Powis, and A. F. Baker
The Thioredoxin-1 Inhibitor 1-Methylpropyl 2-Imidazolyl Disulfide (PX-12) Decreases Vascular Permeability in Tumor Xenografts Monitored by Dynamic Contrast Enhanced Magnetic Resonance Imaging
Clin. Cancer Res., January 15, 2005; 11(2): 529 - 536.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
E. Escalona-Benz, M.-E. Jockovich, T. G. Murray, B. Hayden, E. Hernandez, W. Feuer, and J. J. Windle
Combretastatin A-4 Prodrug in the Treatment of a Murine Model of Retinoblastoma
Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 8 - 11.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Gourdeau, L. Leblond, B. Hamelin, C. Desputeau, K. Dong, I. Kianicka, D. Custeau, C. Boudreau, L. Geerts, S.-X. Cai, et al.
Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents
Mol. Cancer Ther., November 1, 2004; 3(11): 1375 - 1384.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Varterasian, H. Fingert, M. Agin, M. Meyer, M. Cooney, T. Radivoyevitch, A. Dowlati, B. Overmoyer, N. Levitan, K. Robertson, et al.
Consideration of QT/QTc Interval Data in a Phase I Study in Patients with Advanced Cancer
Clin. Cancer Res., September 1, 2004; 10(17): 5967 - 5969.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-C. Kuo, H.-P. Hsieh, W.-Y. Pan, C.-P. Chen, J.-P. Liou, S.-J. Lee, Y.-L. Chang, L.-T. Chen, C.-T. Chen, and J.-Y. Chang
BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activity in Vivo
Cancer Res., July 1, 2004; 64(13): 4621 - 4628.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. A. Horner, S. Gould, J. P. Noakes, N. J. Rattray, S. L. Allen, E. Zotova, and J. C. Arezzo
Lack of neurotoxicity of the vascular targeting agent ZD6126 following repeated i.v. dosing in the rat
Mol. Cancer Ther., July 1, 2004; 3(7): 783 - 791.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. L. Evelhoch, P. M. LoRusso, Z. He, Z. DelProposto, L. Polin, T. H. Corbett, P. Langmuir, C. Wheeler, A. Stone, J. Leadbetter, et al.
Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126
Clin. Cancer Res., June 1, 2004; 10(11): 3650 - 3657.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. G. Kirwan, P. M. Loadman, D. J. Swaine, D. A. Anthoney, G. R. Pettit, J. W. Lippert III, S. D. Shnyder, P. A. Cooper, and M. C. Bibby
Comparative Preclinical Pharmacokinetic and Metabolic Studies of the Combretastatin Prodrugs Combretastatin A4 Phosphate and A1 Phosphate
Clin. Cancer Res., February 15, 2004; 10(4): 1446 - 1453.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. E. Thorpe
Vascular Targeting Agents as Cancer Therapeutics
Clin. Cancer Res., January 15, 2004; 10(2): 415 - 427.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. M. Cooney, T. Radivoyevitch, A. Dowlati, B. Overmoyer, N. Levitan, K. Robertson, S. L. Levine, K. DeCaro, C. Buchter, A. Taylor, et al.
Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer
Clin. Cancer Res., January 1, 2004; 10(1): 96 - 100.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. Stevenson, M. Rosen, W. Sun, M. Gallagher, D. G. Haller, D. Vaughn, B. Giantonio, R. Zimmer, W. P. Petros, M. Stratford, et al.
Phase I Trial of the Antivascular Agent Combretastatin A4 Phosphate on a 5-Day Schedule to Patients With Cancer: Magnetic Resonance Imaging Evidence for Altered Tumor Blood Flow
J. Clin. Oncol., December 1, 2003; 21(23): 4428 - 4438.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
H. Nambu, R. Nambu, M. Melia, and P. A. Campochiaro
Combretastatin A-4 Phosphate Suppresses Development and Induces Regression of Choroidal Neovascularization
Invest. Ophthalmol. Vis. Sci., August 1, 2003; 44(8): 3650 - 3655.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Collins
Functional Imaging in Phase I Studies: Decorations or Decision Making?
J. Clin. Oncol., August 1, 2003; 21(15): 2807 - 2809.
[Full Text] [PDF]

Home page
 JCOHome page
G. J.S. Rustin, S. M. Galbraith, H. Anderson, M. Stratford, L. K. Folkes, L. Sena, L. Gumbrell, and P. M. Price
Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results
J. Clin. Oncol., August 1, 2003; 21(15): 2815 - 2822.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. M. Galbraith, R. J. Maxwell, M. A. Lodge, G. M. Tozer, J. Wilson, N. J. Taylor, J. J. Stirling, L. Sena, A. R. Padhani, and G. J.S. Rustin
Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging
J. Clin. Oncol., August 1, 2003; 21(15): 2831 - 2842.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Braga-Basaria and M. D. Ringel
Beyond Radioiodine: A Review of Potential New Therapeutic Approaches for Thyroid Cancer
J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1947 - 1960.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.